Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid

Just as the dust had settled around Pfizer’s brief Metsera bidding war with Novo Nordisk, another planned biopharma acquisition has been thrust into uncertainty by a surprise counteroffer. Lundbeck is cutting in on Alkermes' proposed purchase of its …

Game on: Lundbeck steps between Alkermes, Avadel with higher bid

The pricier offer by Lundbeck A/S for Avadel Pharmaceuticals plc – which follows last month’s agreement for a takeover by Alkermes plc – had Wall Street buzzing as pundits weighed the odds for each suitor. BioWorld Deals and M&A Neurology/ …

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its approved therapy for the sleep disorder narcolepsy. Lundbeck's unsolicited offer has come in at $23 per share, above …

Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal

Today, a brief rundown of news from Pfizer and Alkermes, as well as updates from Kura Oncology, Gilead Sciences and Zealand Pharma that you may have missed. Pfizer said Thursday it has closed its $10 billion deal to acquire GLP-1 drug developer Metsera, …

Alkermes weighs options after Lundbeck’s higher bid for Avadel

Audio By Carbonatix By Kamal Choudhury (Reuters) -Alkermes said on Friday it is reviewing its options after Avadel Pharmaceuticals received an unsolicited takeover proposal from Danish drugmaker Lundbeck that tops Alkermes’ agreed-upon deal. Shares of …

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

Avadel Pharmaceuticals plc (NASDAQ:AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share. The deal consideration includes $21 per share in cash and a non-transferable contingent value right (CVR) of …

Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel

There’s something in the water in pharma boardrooms. Another bidding war has broken out, this time for sleep biotech Avadel Pharmaceuticals. Lundbeck has submitted an unsolicited proposal to buy Avadel for about $2.42 billion, according to S&P Capital …

Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech Avadel

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes

Avadel Pharmaceuticals Plc (AVDL) said on Friday that it has received an unsolicited proposal from H. Lundbeck A/S to acquire the drugmaker for up to $23 per share. Avadel’s board of directors is of the opinion that the fresh proposal would reasonably …

Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel

(Reuters) -Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck. Shares of Avadel soared over 20% in premarket …